Copy Right: The Authors retain the copyrights of this article, with first publication rights granted to Medsci Publications. License Term: Creative Commons Attribution-Share Alike (CC BY-SA) 4.0 Publisher: Medsci Publications [www.medscipublications.com] ISSN: 2249 4995 Official website: www.njmr.in National Journal of Medical Research | Volume 15 | Issue 04 | October-December 2025 337 Pharmacological Factors that May Influence Myocardial Changes Associated with Atherosclerosis Cihan Bedel 1* , Hatice Aslı Bedel 2 1 Health Science University, Istanbul, Turkey 2 Department of Pharmacology, Suleyman Demirel University, Faculty of Pharmacy, Isparta, Turkey Keywords: Atherosclerosis, Myocardial changes, Pharmacological factors DOI: 10.55489/njmr.150420251187 *Corresponding author: Cihan Bedel, Email: cihanbedel32@gmail.com Date of Submission: 11/08/2025; Date of Acceptance: 02/09/2025; Date of Publication: 01/10/2025 How to cite this article: Bedel C, Bedel HA. Pharmacological Factors that May Influence Myocardial Changes Associated with Ath- erosclerosis. Natl J Med Res 2025;15(04):337-337. DOI: 10.55489/njmr.150420251187 Sir, We read with great interest the article recently published by Patel et al. entitled “Histological and Morphometric Analysis with Grading of Atherosclerosis-Associated My- ocardial Changes in Cases of Sudden Death at a Tertiary Care Hospital”.[1] They found that a comprehensive evaluation combining histological grading and morpho- metric analysis is crucial for a thorough understanding of atherosclerosis-related myocardial changes. We con- gratulate them for their valuable contributions to the lit- erature. Drugs can significantly influence myocardial changes associated with atherosclerosis through various mecha- nisms, including lipid-lowering, immunomodulation, and targeted drug delivery. Statins, COX inhibitors, and bisphosphonates are among the drugs that have been studied for their effects on atherosclerosis and myocar- dial infarction. Each of these drugs interacts with the pathophysiological processes of atherosclerosis in unique ways.[2] A plethora of studies have been conducted on the rela- tionship between bisphosphonates, particularly alendro- nate, and myocardial infarction as well as atherosclero- sis. Adherence to alendronate has been demonstrated to be a significant predictor of cardiovascular health out- comes.[3] Statins have been demonstrated to exert a pleiotropic effect on the human aorta, with a significant reduction in aortic intimal thickness and macrophage counts, thereby suggesting regression of atherosclero- sis. In coronary arteries, statin therapy was associated with a decrease in high-grade plaque and an increase in fibrous plaque, suggesting increased plaque stabilization and reduced inflammation. [4,5] We believe that it would be appropriate for the authors to also address these fac- tors associated with morphological change. REFERENCES 1. Patel P, Jhaveri S, Patel P. Histological and Morphometric Analysis with Grading of Atherosclerosis-Associated Myocardial Changes in Cases of Sud-den Death at a Tertiary Care Hospital. Natl J Med Res 2025;15(03):202-208. DOI: https://doi.org/10.55489/njmr. 150320251125 2. Luz PL, Nishiyama M, Chagas AC. Drugs and lifestyle for the treatment and prevention of coronary artery disease: comparative analysis of the scientific basis. Braz J Med Biol Res. 2011 Oct;44 (10):973-991. DOI: https://doi.org/10.1590/S0100-879X201100750 0111 PMid:21876872 3. Kim DH, Rogers JR, Fulchino LA, Kim CA, Solomon DH, Kim SC. Bisphosphonates and risk of cardiovascular events: a meta- analysis. PLoS One. 2015;10(4):e0122646. DOI: https://doi.org/10. 1371/journal.pone.0122646 PMid:25884398 PMCid:PMC4401508 4. Nissen SE, Nicholls SJ, Sipahi I, Libby P, Raichlen JS, Ballantyne CM, et al. Effect of very high-intensity statin therapy on regression of coronary atherosclerosis: the ASTEROID trial. JAMA. 2006; 295 (13):1556-65. DOI: https://doi.org/10.1001/jama.295.13.jpc60002 PMid:16533939 5. Malakar AK, Choudhury D, Halder B, Paul P, Uddin A, Chakraborty S. A review on coronary artery disease, its risk factors, and thera- peutics. J Cell Physiol. 2019 Aug;234(10):16812-16823. DOI: https://doi.org/10.1002/jcp.28350 PMid:30790284 LETTER TO EDITOR